Safety and Efficacy of COVID‑19 Vaccines Among Patients with Multiple Sclerosis: Letter to Editor

Omid Mirmosayyeb, Elham Moases Ghaffary, Aram Zabeti, Vahid Shaygannejad

Abstract


Dear Editor, Coronavirus disease 2019 (COVID‑19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection. SARS‑CoV‑2 is a member of the RNA family called Coronaviridae, which has swept the world from December 2019 onward.[1] Due to the morbidity, mortality, no definite therapy, and multiple problems that the virus has caused worldwide, most countries have tried to make vaccines with various technologies and methods.[

Keywords


COVID‑19; Efficacy; Multiple Sclerosis; Safety; Vaccines;

Full Text:

PDF

References


Mirmosayyeb O, Ghaffary E, Vaheb S, Pourkazemi R, Shaygannejad V. Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID 19 vaccines: A systematic review. Rev Neurol (Paris) 2023;179:265 81.

Wu X, Wang L, Shen L, Tang K. Response of COVID 19 vaccination in multiple sclerosis patients following disease modifying therapies: A meta analysis. EBioMedicine 2022;81:104102.

Gombolay GY, Dutt M, Tyor W. Immune responses to SARS CoV 2 vaccination in multiple sclerosis: A systematic review/meta analysis. Ann Clin Transl Neurol 2022;9:1321 31.

Jaber A, Patel M, Sylvester A, Yarussi M, Kalina JT, Mendoza JP, et al. COVID 19 vaccine response in people with multiple sclerosis treated with dimethyl fumarate, diroximel fumarate, natalizumab, ocrelizumab, or interferon beta therapy. Neurol Ther 2023;12:687 700.

Elias LB, Jaber A, Manzano M, Leekoff M, Sylvester A, Tremblay MA. Real world efficacy of COVID 19 pre exposure prophylaxis with tixagevimab/cilgavimab in people with multiple sclerosis. Vaccines (Basel) 2023;11:1855.

Stefanou MI, Palaiodimou L, Theodorou A, Christodoulou MV, Tzartos JS, Tzanetakos D, et al. Safety of COVID 19 vaccines in multiple sclerosis: A systematic review and meta analysis. Mult Scler 2023;29:585 94.